Literature DB >> 27604252

Elucidating the gut microbiome of ulcerative colitis: bifidobacteria as novel microbial biomarkers.

Sabrina Duranti1, Federica Gaiani2, Leonardo Mancabelli1, Christian Milani1, Andrea Grandi3, Angelo Bolchi4, Andrea Santoni4, Gabriele Andrea Lugli1, Chiara Ferrario1, Marta Mangifesta5, Alice Viappiani5, Simona Bertoni3, Valentina Vivo3, Fausta Serafini1, Maria Raffaella Barbaro6, Alessandro Fugazza2, Giovanni Barbara6, Laura Gioiosa7, Paola Palanza7, Anna Maria Cantoni8, Gian Luigi de'Angelis2, Elisabetta Barocelli3, Nicola de'Angelis9, Douwe van Sinderen10, Marco Ventura1, Francesca Turroni11.   

Abstract

Ulcerative colitis (UC) is associated with a substantial alteration of specific gut commensals, some of which may be involved in microbiota-mediated protection. In this study, microbiota cataloging of UC patients by 16S rRNA microbial profiling revealed a marked reduction of bifidobacteria, in particular the Bifidobacterium bifidum species, thus suggesting that this taxon plays a biological role in the aetiology of UC. We investigated this further through an in vivo trial by testing the effects of oral treatment with B. bifidum PRL2010 in a wild-type murine colitis model. TNBS-treated mice receiving 10(9) cells of B. bifidum PRL2010 showed a marked reduction of all colitis-associated histological indices as well as maintenance of mucosal integrity as it was shown by the increase in the expression of many tight junction-encoding genes. The protective role of B. bifidum PRL2010, as well as its sortase-dependent pili, appears to be established through the induction of an innate immune response of the host. These results highlight the importance of B. bifidum as a microbial biomarker for UC, revealing its role in protection against experimentally induced colitis. © FEMS 2016. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  dysbiosis; gut microbiota; intestinal inflammation; metagenomics; probiotic bacteria; ulcerative colitis

Mesh:

Substances:

Year:  2016        PMID: 27604252     DOI: 10.1093/femsec/fiw191

Source DB:  PubMed          Journal:  FEMS Microbiol Ecol        ISSN: 0168-6496            Impact factor:   4.194


  50 in total

1.  Molecular profiling of mucosal tissue associated microbiota in patients manifesting acute exacerbations and remission stage of ulcerative colitis.

Authors:  Sandeep A Walujkar; Shreyas V Kumbhare; Nachiket P Marathe; Dhrati V Patangia; Parimal S Lawate; Renu S Bharadwaj; Yogesh S Shouche
Journal:  World J Microbiol Biotechnol       Date:  2018-05-23       Impact factor: 3.312

Review 2.  Role of Short Chain Fatty Acid Receptors in Intestinal Physiology and Pathophysiology.

Authors:  Medha Priyadarshini; Kumar U Kotlo; Pradeep K Dudeja; Brian T Layden
Journal:  Compr Physiol       Date:  2018-06-18       Impact factor: 9.090

3.  Composite Sophora Colon-Soluble Capsule Ameliorates DSS-Induced Ulcerative Colitis in Mice via Gut Microbiota-Derived Butyric Acid and NCR+ ILC3.

Authors:  Ming-Jun Chen; Yang Feng; Lu Gao; Ming-Xiong Lin; Shi-da Wang; Zhan-Qi Tong
Journal:  Chin J Integr Med       Date:  2022-04-12       Impact factor: 1.978

4.  Exploring the Ecological Effects of Naturally Antibiotic-Insensitive Bifidobacteria in the Recovery of the Resilience of the Gut Microbiota during and after Antibiotic Treatment.

Authors:  Chiara Argentini; Leonardo Mancabelli; Giulia Alessandri; Chiara Tarracchini; Margherita Barbetti; Luca Carnevali; Giulia Longhi; Alice Viappiani; Rosaria Anzalone; Christian Milani; Andrea Sgoifo; Douwe van Sinderen; Marco Ventura; Francesca Turroni
Journal:  Appl Environ Microbiol       Date:  2022-06-02       Impact factor: 5.005

5.  Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial.

Authors:  Cesare Cremon; Simone Guglielmetti; Giorgio Gargari; Valentina Taverniti; Anna Maria Castellazzi; Chiara Valsecchi; Carlotta Tagliacarne; Walter Fiore; Massimo Bellini; Lorenzo Bertani; Dario Gambaccini; Michele Cicala; Bastianello Germanà; Maurizio Vecchi; Isabella Pagano; Maria Raffaella Barbaro; Lara Bellacosa; Vincenzo Stanghellini; Giovanni Barbara
Journal:  United European Gastroenterol J       Date:  2017-10-08       Impact factor: 4.623

6.  Aging, Frailty, and the Microbiome-How Dysbiosis Influences Human Aging and Disease.

Authors:  John P Haran; Beth A McCormick
Journal:  Gastroenterology       Date:  2020-12-08       Impact factor: 22.682

Review 7.  MAP, Johne's disease and the microbiome; current knowledge and future considerations.

Authors:  Chloe Matthews; Paul D Cotter; Jim O' Mahony
Journal:  Anim Microbiome       Date:  2021-05-07

8.  Inflammatory bowel disease biomarkers of human gut microbiota selected via different feature selection methods.

Authors:  Burcu Bakir-Gungor; Hilal Hacılar; Amhar Jabeer; Ozkan Ufuk Nalbantoglu; Oya Aran; Malik Yousef
Journal:  PeerJ       Date:  2022-04-25       Impact factor: 3.061

9.  Dietary fiber intake, the gut microbiome, and chronic systemic inflammation in a cohort of adult men.

Authors:  Curtis Huttenhower; Andrew T Chan; Wenjie Ma; Long H Nguyen; Mingyang Song; Dong D Wang; Eric A Franzosa; Yin Cao; Amit Joshi; David A Drew; Raaj Mehta; Kerry L Ivey; Lisa L Strate; Edward L Giovannucci; Jacques Izard; Wendy Garrett; Eric B Rimm
Journal:  Genome Med       Date:  2021-06-17       Impact factor: 11.117

10.  Bifidobacteria or Fiber Protects against Diet-Induced Microbiota-Mediated Colonic Mucus Deterioration.

Authors:  Bjoern O Schroeder; George M H Birchenough; Marcus Ståhlman; Liisa Arike; Malin E V Johansson; Gunnar C Hansson; Fredrik Bäckhed
Journal:  Cell Host Microbe       Date:  2017-12-21       Impact factor: 31.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.